Containing relevant Learning Zones, guidelines, trials and news.
TECVAYLI is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Tepkinly (epcoritamab), as monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
MigraKind film-coated tablets are indicated for the acute relief of migraine attacks, with or without aura. MigraKind film-coated tablets should only be used where there is a clear diagnosis of migraine.
Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
The head of UNAIDS maintained that Gilead could bring the AIDS pandemic toward an end if the company opens up access to its game-changing new HIV drug, Agence France Presse reports.
STADA and Alvotech have launched Uzpruvo, the first approved biosimilar to Stelara in Europe, across a majority of European countries. This includes the largest markets in the region, where pricing and reimbursement approvals have been secured for market entry
Although data from a phase II trial (NCT05608044) demonstrated that botensilimab plus balstilimab was active in patients with relapsed/refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without liver metastases, the FDA advised against filing for accelerated approval of the combination since the objective response rates (ORRs) may not translate to a survival benefit, according to an announcement from Agenus following an end-of-phase II meeting